Blood Res.  2020 Jul;55(S1):S32-S36. 10.5045/br.2020.S006.

Current treatment strategies for Philadelphia chromosome-positive adult acute lymphoblastic leukemia

• Park HS

• KMID: 2504740
• DOI: http://doi.org/10.5045/br.2020.S006

Abstract

Acute lymphoblastic leukemia (ALL) is an aggressive hematological disease. The incorporation of tyrosine kinase inhibitors (TKIs) into the standard treatment regimen for Philadelphia (Ph)-positive ALL significantly improved clinical outcomes. TKI-based induction chemotherapy, followed by allogeneic hematopoietic cell transplantation (HCT) during the first complete remission (CR), is the standard of care for ALL patients. However, treatment with TKIs alone or TKIs plus low-intensity chemotherapy can achieve CR in some patients. Although this strategy is not enough to induce a deeper molecular response, it can reduce the incidence of treatment-related mortality. Despite promising results from pediatric trials, allogeneic HCT remains an important component of the treatment strategy for Ph-positive adult ALL. However, improving the highly sensitive BCR-ABL1 assays and introducing immunotherapy may decrease the demand for allogeneic HCT. Nevertheless, the treatment of Ph-positive ALL is still challenging, especially in cases with relapsed and refractory disease. Potent TKIs and monoclonal antibodies, such as blinatumomab and inotuzumab, have improved patient outcomes in relapse and refractory cases of ALL. The introduction of effective agents, such as potent TKIs and monoclonal antibodies, may improve the possibility of remission in Ph-positive ALL patients and hopefully cure this disease.

Keyword

Adult acute lymphoblastic leukemia; Philadelphia positive

Reference

1. Annino L, Vegna ML, Camera A, et al. 2002; Treatment of adult acute lymphoblastic leukemia (ALL): long-term follow-up of the GIMEMA ALL 0288 randomized study. Blood. 99:863–71. DOI: 10.1182/blood.V99.3.863. PMID: 11806988.

2. Kantarjian H, Thomas D, O'Brien S, et al. 2004; Long-term follow-up results of hyperfractionated cyclophosphamide, vincristine, doxorubicin, and dexamethasone (Hyper-CVAD), a dose-intensive regimen, in adult acute lymphocytic leukemia. Cancer. 101:2788–801. DOI: 10.1002/cncr.20668. PMID: 15481055.

3. Thomas X, Boiron JM, Huguet F, et al. 2004; Outcome of treatment in adults with acute lymphoblastic leukemia: analysis of the LALA-94 trial. J Clin Oncol. 22:4075–86. DOI: 10.1200/JCO.2004.10.050. PMID: 15353542.

4. Rowe JM, Buck G, Burnett AK, et al. 2005; Induction therapy for adults with acute lymphoblastic leukemia: results of more than 1500 patients from the international ALL trial: MRC UKALL XII/ECOG E2993. Blood. 106:3760–7. DOI: 10.1182/blood-2005-04-1623. PMID: 16105981.

5. Bassan R, Rossi G, Pogliani EM, et al. 2010; Chemotherapy-phased imatinib pulses improve long-term outcome of adult patients with Philadelphia chromosome-positive acute lymphoblastic leukemia: Northern Italy Leukemia Group protocol 09/00. J Clin Oncol. 28:3644–52. DOI: 10.1200/JCO.2010.28.1287. PMID: 20606084.

6. Fielding AK, Rowe JM, Buck G, et al. 2014; UKALLXII/ECOG2993: addition of imatinib to a standard treatment regimen enhances long-term outcomes in Philadelphia positive acute lymphoblastic leukemia. Blood. 123:843–50. DOI: 10.1182/blood-2013-09-529008. PMID: 24277073. PMCID: PMC3916877.

7. Daver N, Thomas D, Ravandi F, et al. 2015; Final report of a phase II study of imatinib mesylate with hyper-CVAD for the front-line treatment of adult patients with Philadelphia chromosome-positive acute lymphoblastic leukemia. Haematologica. 100:653–61. DOI: 10.3324/haematol.2014.118588. PMID: 25682595. PMCID: PMC4420214.

8. Kim DY, Joo YD, Lim SN, et al. 2015; Nilotinib combined with multiagent chemotherapy for newly diagnosed Philadelphia-positive acute lymphoblastic leukemia. Blood. 126:746–56. DOI: 10.1182/blood-2015-03-636548. PMID: 26065651.

9. Ravandi F, O'Brien SM, Cortes JE, et al. 2015; Long-term follow-up of a phase 2 study of chemotherapy plus dasatinib for the initial treatment of patients with Philadelphia chromosome-positive acute lymphoblastic leukemia. Cancer. 121:4158–64. DOI: 10.1002/cncr.29646. PMID: 26308885. PMCID: PMC4666803.

10. Wang J, Jiang Q, Xu LP, et al. 2018; Allogeneic stem cell transplantation versus tyrosine kinase inhibitors combined with chemotherapy in patients with Philadelphia chromosome-positive acute lymphoblastic leukemia. Biol Blood Marrow Transplant. 24:741–50. DOI: 10.1016/j.bbmt.2017.12.777. PMID: 29247779.

11. Litzow MR, Fielding AK, Luger SM, et al. 2017; The evolving role of chemotherapy and hematopoietic cell transplants in Ph-positive acute lymphoblastic leukemia in adults. Bone Marrow Transplant. 52:1592–8. DOI: 10.1038/bmt.2017.110. PMID: 28581459.

12. Stock W. 2010; Current treatment options for adult patients with Philadelphia chromosome-positive acute lymphoblastic leukemia. Leuk Lymphoma. 51:188–98. DOI: 10.3109/10428190903452834. PMID: 20001232.

13. Fielding AK. 2011; Current treatment of Philadelphia chromosome-positive acute lymphoblastic leukemia. Hematology Am Soc Hematol Educ Program. 2011:231–7. DOI: 10.1182/asheducation-2011.1.231. PMID: 22160039.

14. Fielding AK, Rowe JM, Richards SM, et al. 2009; Prospective outcome data on 267 unselected adult patients with Philadelphia chromosome-positive acute lymphoblastic leukemia confirms superiority of allogeneic transplantation over chemotherapy in the pre-imatinib era: results from the International ALL Trial MRC UKALLXII/ECOG2993. Blood. 113:4489–96. DOI: 10.1182/blood-2009-01-199380. PMID: 19244158. PMCID: PMC4188540.

15. Chalandon Y, Thomas X, Hayette S, et al. 2015; Randomized study of reduced-intensity chemotherapy combined with imatinib in adults with Ph-positive acute lymphoblastic leukemia. Blood. 125:3711–9. DOI: 10.1182/blood-2015-02-627935. PMID: 25878120.

16. Ravandi F, Othus M, O'Brien SM, et al. 2016; US Intergroup study of chemotherapy plus dasatinib and allogeneic stem cell transplant in Philadelphia chromosome positive ALL. Blood Adv. 1:250–9. DOI: 10.1182/bloodadvances.2016001495. PMID: 29046900. PMCID: PMC5642915.

17. Lussana F, Intermesoli T, Gianni F, et al. 2016; Achieving molecular remission before allogeneic stem cell transplantation in adult patients with Philadelphia chromosome-positive acute lymphoblastic leukemia: impact on relapse and long-term outcome. Biol Blood Marrow Transplant. 22:1983–7. DOI: 10.1016/j.bbmt.2016.07.021. PMID: 27492792.

18. Lee S, Kim DW, Cho BS, et al. 2012; Impact of minimal residual disease kinetics during imatinib-based treatment on transplantation outcome in Philadelphia chromosome-positive acute lymphoblastic leukemia. Leukemia. 26:2367–74. DOI: 10.1038/leu.2012.164. PMID: 22705993.

19. Nicolini FE, Basak GW, Kim DW, et al. 2017; Overall survival with ponatinib versus allogeneic stem cell transplantation in Philadelphia chromosome-positive leukemias with the T315I mutation. Cancer. 123:2875–80. DOI: 10.1002/cncr.30558. PMID: 28387926. PMCID: PMC5573914.

20. Nishiwaki S, Imai K, Mizuta S, et al. 2016; Impact of MRD and TKI on allogeneic hematopoietic cell transplantation for Ph+ALL: a study from the adult ALL WG of the JSHCT. Bone Marrow Transplant. 51:43–50. DOI: 10.1038/bmt.2015.217. PMID: 26389833.

21. Yoon JH, Min GJ, Park SS, et al. 2019; Minimal residual disease-based long-term efficacy of reduced-intensity conditioning versus myeloablative conditioning for adult Philadelphia-positive acute lymphoblastic leukemia. Cancer. 125:873–83. DOI: 10.1002/cncr.31874. PMID: 30521062.

22. Vignetti M, Fazi P, Cimino G, et al. 2007; Imatinib plus steroids induces complete remissions and prolonged survival in elderly Philadelphia chromosome-positive patients with acute lymphoblastic leukemia without additional chemotherapy: results of the Gruppo Italiano Malattie Ematologiche dell'Adulto (GIMEMA) LAL0201-B protocol. Blood. 109:3676–8. DOI: 10.1182/blood-2006-10-052746. PMID: 17213285.

23. Foà R, Vitale A, Vignetti M, et al. 2011; Dasatinib as first-line treatment for adult patients with Philadelphia chromosome-positive acute lymphoblastic leukemia. Blood. 118:6521–8. DOI: 10.1182/blood-2011-05-351403. PMID: 21931113.

24. Chiaretti S, Vitale A, Vignetti M, et al. 2016; A sequential approach with imatinib, chemotherapy and transplant for adult Ph+ acute lymphoblastic leukemia: final results of the GIMEMA LAL 0904 study. Haematologica. 101:1544–52. DOI: 10.3324/haematol.2016.144535. PMID: 27515250. PMCID: PMC5479612.

25. Rousselot P, Coudé MM, Gokbuget N, et al. 2016; Dasatinib and low-intensity chemotherapy in elderly patients with Philadelphia chromosome-positive ALL. Blood. 128:774–82. DOI: 10.1182/blood-2016-02-700153. PMID: 27121472. PMCID: PMC5085255.

26. Jabbour E, Kantarjian H, Ravandi F, et al. 2015; Combination of hyper-CVAD with ponatinib as first-line therapy for patients with Philadelphia chromosome-positive acute lymphoblastic leukaemia: a single-centre, phase 2 study. Lancet Oncol. 16:1547–55. DOI: 10.1016/S1470-2045(15)00207-7. PMID: 26432046. PMCID: PMC4816046.

27. Martinelli G, Iacobucci I, Storlazzi CT, et al. 2009; IKZF1 (Ikaros) deletions in BCR-ABL1-positive acute lymphoblastic leukemia are associated with short disease-free survival and high rate of cumulative incidence of relapse: a GIMEMA AL WP report. J Clin Oncol. 27:5202–7. DOI: 10.1200/JCO.2008.21.6408. PMID: 19770381.

28. Pfeifer H, Raum K, Markovic S, et al. 2018; Genomic CDKN2A/2B deletions in adult Ph+ ALL are adverse despite allogeneic stem cell transplantation. Blood. 131:1464–75. DOI: 10.1182/blood-2017-07-796862. PMID: 29348129.

29. Fedullo AL, Messina M, Elia L, et al. 2019; Prognostic implications of additional genomic lesions in adult Philadelphia chromosome-positive acute lymphoblastic leukemia. Haematologica. 104:312–8. DOI: 10.3324/haematol.2018.196055. PMID: 30190342. PMCID: PMC6355475.

30. Schultz KR, Carroll A, Heerema NA, et al. 2014; Long-term follow-up of imatinib in pediatric Philadelphia chromosome-positive acute lymphoblastic leukemia: Children's Oncology Group study AALL0031. Leukemia. 28:1467–71. DOI: 10.1038/leu.2014.30. PMID: 24441288. PMCID: PMC4282929.

31. Slayton WB, Schultz KR, Kairalla JA, et al. 2018; Dasatinib plus intensive chemotherapy in children, adolescents, and young adults with philadelphia chromosome-positive acute lymphoblastic leukemia: results of Children's Oncology Group Trial AALL0622. J Clin Oncol. 36:2306–14. DOI: 10.1200/JCO.2017.76.7228. PMID: 29812996. PMCID: PMC6067800.

32. Jabbour E, Short NJ, Ravandi F, et al. 2018; Combination of hyper-CVAD with ponatinib as first-line therapy for patients with Philadelphia chromosome-positive acute lymphoblastic leukaemia: long-term follow-up of a single-centre, phase 2 study. Lancet Haematol. 5:e618–27. DOI: 10.1016/S2352-3026(18)30176-5. PMID: 30501869.

33. Kadia TM, Kantarjian HM, Thomas DA, et al. 2015; Phase II study of methotrexate, vincristine, pegylated-asparaginase, and dexamethasone (MOpAD) in patients with relapsed/refractory acute lymphoblastic leukemia. Am J Hematol. 90:120–4. DOI: 10.1002/ajh.23886. PMID: 25368968. PMCID: PMC4447180.

34. Thomas DA, Kantarjian H, Smith TL, et al. 1999; Primary refractory and relapsed adult acute lymphoblastic leukemia: characteristics, treatment results, and prognosis with salvage therapy. Cancer. 86:1216–30. DOI: 10.1002/(SICI)1097-0142(19991001)86:7<1216::AID-CNCR17>3.0.CO;2-O. PMID: 10506707.

35. Fielding AK, Richards SM, Chopra R, et al. 2007; Outcome of 609 adults after relapse of acute lymphoblastic leukemia (ALL); an MRC UKALL12/ECOG 2993 study. Blood. 109:944–50. DOI: 10.1182/blood-2006-05-018192. PMID: 17032921.

36. Tavernier E, Boiron JM, Huguet F, et al. 2007; Outcome of treatment after first relapse in adults with acute lymphoblastic leukemia initially treated by the LALA-94 trial. Leukemia. 21:1907–14. DOI: 10.1038/sj.leu.2404824. PMID: 17611565.

37. Martinelli G, Boissel N, Chevallier P, et al. 2017; Complete hematologic and molecular response in adult patients with relapsed/refractory philadelphia chromosome-positive B-precursor acute lymphoblastic leukemia following treatment with blinatumomab: results from a phase II, single-arm, multicenter study. J Clin Oncol. 35:1795–802. DOI: 10.1200/JCO.2016.69.3531. PMID: 28355115.

38. Assi R, Kantarjian H, Short NJ, et al. 2017; Safety and efficacy of blinatumomab in combination with a tyrosine kinase inhibitor for the treatment of relapsed Philadelphia chromosome-positive leukemia. Clin Lymphoma Myeloma Leuk. 17:897–901. DOI: 10.1016/j.clml.2017.08.101. PMID: 28927784.

39. Rambaldi A, Ribera JM, Kantarjian HM, et al. 2020; Blinatumomab compared with standard of care for the treatment of adult patients with relapsed/refractory Philadelphia chromosome-positive B-precursor acute lymphoblastic leukemia. Cancer. 126:304–10. DOI: 10.1002/cncr.32558. PMID: 31626339. PMCID: PMC7003760.

40. Kantarjian HM, DeAngelo DJ, Stelljes M, et al. 2016; Inotuzumab ozogamicin versus standard therapy for acute lymphoblastic leukemia. N Engl J Med. 375:740–53. DOI: 10.1056/NEJMoa1509277. PMID: 27292104. PMCID: PMC5594743.

41. Park JH, Rivière I, Gonen M, et al. 2018; Long-term follow-up of CD19 CAR therapy in acute lymphoblastic leukemia. N Engl J Med. 378:449–59. DOI: 10.1056/NEJMoa1709919. PMID: 29385376. PMCID: PMC6637939.

42. Jacoby E. 2019; The role of allogeneic HSCT after CAR T cells for acute lymphoblastic leukemia. Bone Marrow Transplant. 54(Suppl 2):810–4. DOI: 10.1038/s41409-019-0604-3. PMID: 31431700.

43. Ruella M, Maus MV. 2016; Catch me if you can: leukemia escape after CD19-directed T cell immunotherapies. Comput Struct Biotechnol J. 14:357–62. DOI: 10.1016/j.csbj.2016.09.003. PMID: 27761200. PMCID: PMC5061074.